Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CDMO NASDAQ:CRNX NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$40.50+5.0%$41.07$16.50▼$48.45$3.76BN/A38,654 shs11,042 shsCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsCRNXCrinetics Pharmaceuticals$35.66+4.1%$30.26$24.10▼$62.53$3.36B0.28952,842 shs970,849 shsIMVTImmunovant$17.11+6.1%$16.29$12.72▼$34.47$2.98B0.451.47 million shs1.46 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-6.61%-6.20%-8.14%+35.94%+3,857,999,900.00%CDMOAvid Bioservices0.00%0.00%0.00%0.00%+35.23%CRNXCrinetics Pharmaceuticals-1.15%+11.75%+17.13%+3.76%-35.13%IMVTImmunovant-3.47%+8.77%-2.36%-3.88%-47.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$40.50+5.0%$41.07$16.50▼$48.45$3.76BN/A38,654 shs11,042 shsCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsCRNXCrinetics Pharmaceuticals$35.66+4.1%$30.26$24.10▼$62.53$3.36B0.28952,842 shs970,849 shsIMVTImmunovant$17.11+6.1%$16.29$12.72▼$34.47$2.98B0.451.47 million shs1.46 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-6.61%-6.20%-8.14%+35.94%+3,857,999,900.00%CDMOAvid Bioservices0.00%0.00%0.00%0.00%+35.23%CRNXCrinetics Pharmaceuticals-1.15%+11.75%+17.13%+3.76%-35.13%IMVTImmunovant-3.47%+8.77%-2.36%-3.88%-47.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCRNXCrinetics Pharmaceuticals 2.78Moderate Buy$68.8693.12% UpsideIMVTImmunovant 2.83Moderate Buy$33.6096.43% UpsideCurrent Analyst Ratings BreakdownLatest CDMO, IMVT, AAPG, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/11/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$90.00 ➝ $86.007/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$36.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M28.02N/AN/A$0.48 per share84.38CDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CRNXCrinetics Pharmaceuticals$1.04M3,228.83N/AN/A$14.29 per share2.50IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)Latest CDMO, IMVT, AAPG, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACDMOAvid BioservicesN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53CDMOAvid Bioservices3.581.300.92CRNXCrinetics PharmaceuticalsN/A17.8017.80IMVTImmunovantN/A12.3212.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACDMOAvid Bioservices97.16%CRNXCrinetics Pharmaceuticals98.51%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACDMOAvid Bioservices3.05%CRNXCrinetics Pharmaceuticals4.60%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60092.96 millionN/AN/ACDMOAvid Bioservices32063.96 million62.01 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableIMVTImmunovant120174.32 million171.18 millionOptionableCDMO, IMVT, AAPG, and CRNX HeadlinesRecent News About These CompaniesIMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study ResultsSeptember 4 at 12:11 PM | zacks.comADAR1 Capital Management LLC Has $16.56 Million Position in Immunovant, Inc. $IMVTSeptember 4 at 7:41 AM | marketbeat.comRedmile Group LLC Cuts Stake in Immunovant, Inc. $IMVTSeptember 4 at 7:28 AM | marketbeat.comVestal Point Capital LP Buys 305,000 Shares of Immunovant, Inc. $IMVTSeptember 4 at 7:17 AM | marketbeat.comBaker BROS. Advisors LP Boosts Holdings in Immunovant, Inc. $IMVTSeptember 4 at 6:27 AM | marketbeat.comInvesco Ltd. Has $945,000 Holdings in Immunovant, Inc. $IMVTSeptember 4 at 3:07 AM | marketbeat.comImmunovant: 80% of patients demonstrate response in Graves’ disease trialSeptember 4 at 2:18 AM | msn.comRoivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data TranscriptSeptember 3 at 12:03 AM | seekingalpha.comImmunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsSeptember 3 at 12:57 PM | globenewswire.comOMERS ADMINISTRATION Corp Acquires Shares of 48,300 Immunovant, Inc. $IMVTSeptember 3 at 4:42 AM | marketbeat.comFinancial Survey: Immunovant (NASDAQ:IMVT) & Adlai Nortye (NASDAQ:ANL)September 3 at 2:11 AM | americanbankingnews.comImmunovant, Inc. $IMVT Holdings Boosted by Alpine Global Management LLCSeptember 2 at 8:55 AM | marketbeat.comRafferty Asset Management LLC Acquires 22,213 Shares of Immunovant, Inc. $IMVTSeptember 2 at 5:05 AM | marketbeat.comDAFNA Capital Management LLC Purchases 62,000 Shares of Immunovant, Inc. $IMVTSeptember 1, 2025 | marketbeat.com233,985 Shares in Immunovant, Inc. $IMVT Purchased by Nuveen LLCAugust 30, 2025 | marketbeat.comRoivant Sciences (ROIV) Announces Q1 2025 Business UpdateAugust 29, 2025 | finance.yahoo.comAnalysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $35.20August 29, 2025 | americanbankingnews.comImmunovant Stockholders Approve Key Governance DecisionsAugust 28, 2025 | tipranks.comImmunovant, Inc. $IMVT Shares Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comJump Financial LLC Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDMO, IMVT, AAPG, and CRNX Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$40.50 +1.92 (+4.98%) As of 01:48 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Avid Bioservices NASDAQ:CDMOAvid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Crinetics Pharmaceuticals NASDAQ:CRNX$35.66 +1.41 (+4.10%) Closing price 03:59 PM EasternExtended Trading$35.63 -0.02 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Immunovant NASDAQ:IMVT$17.10 +0.99 (+6.11%) Closing price 03:59 PM EasternExtended Trading$17.14 +0.03 (+0.18%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
